Approved accessible "sotorasib tablets"

Sotorasib is indicated for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by a Food and Drug Administration-approved test, who have received at least one prior systemic therapy. Sotorasib is an anti-cancer medication used to treat non-small-cell lung cancer. It targets a specific mutation, G12C, in the protein K-Ras encoded by gene KRAS which is responsible for various forms of cancer. Sotorasib is an inhibitor of the RAS GTPase family. The most common side effects include diarrhea, musculoskeletal pain, nausea, fatigue, liver damage and cough.

Sotorasib was approved for medical use in the United States in May 2021, and in the European Union in January 2022. The US Food and Drug Administration considers it to be a first-in-class medication.

How can 1 go about obtaining Sotorasib tablets?

If Sotorasib tablets are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

Lumakras (sotorasib tablets) for oral use Initial U.S. Approval: 2021